Transgenomic's Q4 Sales Rise 9.4 Percent | GenomeWeb
NEW YORK (GenomeWeb News) - Transgenomic today said fourth-quarter revenues increased 9.4 percent as R&D spending rose roughly 28 percent and losses were cut by 91 percent.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $5.8 million from $5.3 million year over year.
  
The growth came from sales of the company’s Discovery Services unit, OEM sales, and placements of the company’s WAVE system and related consumables, Transgenomic CEO Craig Tuttle said in a statement.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.